Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
WAT Medical introduces ObeEnd, a revolutionary weight management wristband supported by clinical evidence. The device aims to address the global obesity epidemic by providing a drug-free, effective solution. ObeEnd utilizes neuromodulation technology to reduce caloric intake and enhance post-exercise recovery, showing promising results in clinical studies. The groundbreaking innovation marks a major milestone in the field of weight management.
Waters announced the release of the ACQUITY QDa II Mass Detector, a cost-effective, energy-efficient instrument that enhances compound identification through mass analysis. The new detector offers a 20% increase in mass range, up to 70% lower energy consumption, and is recognized for sustainability by My Green Lab.
Waters (NYSE: WAT) reported first-quarter 2024 financial results with sales of $637 million, a 7% decline, but at the high end of guidance. GAAP EPS was $1.72, well above guidance, with non-GAAP EPS of $2.21. Operational excellence led to gross margin expansion. Full-year guidance maintained for -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05.